RSV Vaccines for the World

14-16 October 2013, Tiara Park Atlantico Hotel, Porto, Portugal

  • Increase font size
  • Default font size
  • Decrease font size

Introduction

Human respiratory syncytial virus (HRSV) is a major cause of upper and lower respiratory tract illness in infants and young children worldwide. Despite its importance as a respiratory pathogen, there is currently no licensed vaccine for prophylaxis of HRSV infection. There are several hurdles complicating the development of a RSV vaccine: 1) incomplete immunity to natural RSV infection leading to frequent re-infection, 2) immature immune system and maternal antibodies of newborn infants who are the primary subject population, and 3) imbalanced Th2-biased immune responses to a past vaccine candidate led to exacerbated pulmonary disease. After the failure of an initial trial featuring formalin-inactivated virus as a RSV vaccine, more careful and deliberate efforts have been made towards the development of safe and effective RSV vaccines without vaccine-enhanced disease. Currently a wide array of RSV vaccine strategies is being developed, including live-attenuated viruses, protein subunit-based, and vector-based candidates. Though licensed vaccines remain to be developed, concerted efforts will lead researchers to reach the goal of attaining safe and effective RSV vaccines in the near future.

This new international conference will aim to bring together RSV researchers and other interested parties and researchers to hear updates on progress towards the successful implementation of vaccines/vaccine strategies against the RSV pathogen. RSVVW 2013 will be of interest to researchers/contributors from academic programmes, industrial, governmental and regulatory groups.

The RSVVW 2013 meeting will comprise keynote presentations and special sessions and in addition the RSVVW 2013 organisers invite oral and poster abstract submissions to be considered for inclusion in the meeting schedule.

Scientific Advisory Panel

Greg Glenn (Novavax Inc., Rockville, Maryland, USA)
Deborah Higgins (PATH, Seattle, Washington, USA)
James Crowe (Vanderbilt University, Nashville, Tennessee, USA)
Barney Graham (NIH, Bethesda, Maryland, USA)
Ruth Karron (Johns Hopkins University, Baltimore, Maryland, USA)
Philip Dormitzer (Novartis Vaccines & Diagnostics, Cambridge, Massachusetts, USA)
Trudy Morrison (University of Massachusetts, Worcester, Massachusetts, USA)
Alexis Kalergis (Pontificia Universidad Catolica de Chile/University of Nantes, France)
Sylvain Fleury (Mymetics Corporation, Epalinges, Switzerland)
Ali Fattom (NanoBio Corporation, Ann Arbor, Michigan, USA)
Sylvia van den Hurk (VIDO, University of Saskatchewan, Canada)
Kees Leenhouts (Mucosis, Groningen, The Netherlands)
Rob Lambkin-Williams (Retroscreen Virology Ltd, London, UK)
Peter Openshaw (Imperial College, London, UK)
Judy Beeler (CBER/FDA, Bethesda, Maryland, USA)
Peter F. Wright (Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA)
Edward E. Walsh (Rochestyer General Hospital, Rochester, New York, USA)
Janet Englund (Seattle Children’s Hospital, Seattle, Washington, USA)
Peter Collins (NIAID/NIH, Bethesda, Maryland, USA)
Jean-Francois Toussaint (GSK Vaccines, Rixensart, Belgium)
James Nokes (KEMRI-WT, Kilifi, Kenya/Warwick University, Coventry, UK)
Steven Varga (University of Iowa, Iowa City, Iowa, USA)

Conference Scope

The RSVVW 2013 meeting is aimed at attracting a broader audience of RSV researchers and also vaccinologists/groups not necessarily directly involved with RSV research. The main topics/sessions will include:

  • Lessons learned from previous vaccine developments
  • Requirements induction of protective, safe and durable immune responses
  • Populations needing a vaccine and strategies for delivery
  • Infant Immunization – Maternal Immunization – Elderly Immunization
  • Current vaccines development
  • Clinical development of RSV vaccines: hurdles, opportunities and dead ends
  • Animal and challenge models
  • Antigens, adjuvants and vaccine approaches
  • RSV vaccines in the developing world

You may also be interested in…

The 9th International Respiratory Syncytial Virus Symposium

The theme of the 9th symposium is “RSV: A global health problem”, which brings attention to the problem of RSV in both industrialised and developing countries. The programme will cover a broad range of topics.

The conference will be held in Cape Town, South Africa between the 9th and 13th November 2014 and is organised by the South African Paediatric Infectious Disease Society.

To find out more, please visit www.rsv2014.co.za.

 

RSVVW 2013 Delegates

Login details will be supplied after you have registered for the event.


RSVVW 2013 Sponsors

  • ADMA Biologics
  • VLP Biotech
  • Retroscreen Virology
  • Mymetics
  • PATH
  • Inovio Pharmaceuticals
  • Mucosis
  • Ablynx
  • Novavax
  • Pevion Vaccines
  • Aldevron
  • NatureGeneTherapy.com
  • Sanofi Pasteur
  • Novartis Vaccines
  • Okairos
  • Crucell
  • Immunovaccine
  • NanoBio

RSVVW 2013 Downloads

RSVVW 2013 Leaflet

RSVVW 2013 Mailing List

Name
E-mail Address
What is 1+4-2?